VBL Therapeutics

VBL Therapeutics develops targeted therapies for immune-inflammatory diseases and solid tumors. Its lead immunology candidate, VB‑601, leverages a proprietary monocyte targeting technology to limit chronic inflammation and was expected to enter Phase I trials in late 2022. The company’s previous lead oncology program, VB‑111 (ofranergene obadenovec), a gene therapy for solid tumors such as recurrent glioblastoma and platinum-resistant ovarian cancer, reported disappointing results in a Phase III trial for ovarian cancer in July 2022. The company continues to advance its immunology pipeline while evaluating next steps for its oncology assets[1][3][5].